|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brenton JD, Carey LA, Ahmed AA and Caldas
C: Molecular classification and molecular forecasting of breast
cancer: Ready for clinical application? J Clin Oncol. 23:7350–7360.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shah SP, Roth A, Goya R, Oloumi A, Ha G,
Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, et al: The clonal
and mutational evolution spectrum of primary triple-negative breast
cancers. Nature. 486:395–399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gluz O, Liedtke C, Gottschalk N, Pusztai
L, Nitz U and Harbeck N: Triple-negative breast cancer-current
status and future directions. Ann Oncol. 20:1913–1927. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Berry DA, Cirrincione C, Henderson IC,
Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB,
Norton L, et al: Estrogen-receptor status and outcomes of modern
chemotherapy for patients with node-positive breast cancer. JAMA.
295:1658–1667. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nabholtz JM, Abrial C, Mouret-Reynier MA,
Dauplat MM, Weber B, Gligorov J, Forest AM, Tredan O, Vanlemmens L,
Petit T, et al: Multicentric neoadjuvant phase II study of
panitumumab combined with an anthracycline/taxane-based
chemotherapy in operable triple-negative breast cancer:
Identification of biologically defined signatures predicting
treatment impact. Ann Oncol. 25:1570–1577. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Torrisi R, Balduzzi A, Ghisini R, Rocca A,
Bottiglieri L, Giovanardi F, Veronesi P, Luini A, Orlando L, Viale
G, et al: Tailored preoperative treatment of locally advanced
triple negative (hormone receptor negative and HER2 negative)
breast cancer with epirubicin, cisplatin, and infusional
fluorouracil followed by weekly paclitaxel. Cancer Chemother
Pharmacol. 62:667–672. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Burstein MD, Tsimelzon A, Poage GM,
Covington KR, Contreras A, Fuqua SA, Savage MI, Osborne CK,
Hilsenbeck SG, Chang JC, et al: Comprehensive genomic analysis
identifies novel subtypes and targets of triple-negative breast
cancer. Clin Cancer Res. 21:1688–1698. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tsimberidou AM, Iskander NG, Hong DS,
Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra
R, et al: Personalized medicine in a phase I clinical trials
program: The MD Anderson cancer center initiative. Clin Cancer Res.
18:6373–6383. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jovanović B, Beeler JS, Pickup MW, Chytil
A, Gorska AE, Ashby WJ, Lehmann BD, Zijlstra A, Pietenpol JA and
Moses HL: Transforming growth factor beta receptor type III is a
tumor promoter in mesenchymal-stem like triple negative breast
cancer. Breast Cancer Res. 16:R692014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Litzenburger BC, Creighton CJ, Tsimelzon
A, Chan BT, Hilsenbeck SG, Wang T, Carboni JM, Gottardis MM, Huang
F, Chang JC, et al: High IGF-IR activity in triple-negative breast
cancer cell lines and tumorgrafts correlates with sensitivity to
anti-IGF-IR therapy. Clin Cancer Res. 17:2314–2327. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sharpe R, Pearson A, Herrera-Abreu MT,
Johnson D, Mackay A, Welti JC, Natrajan R, Reynolds AR, Reis-Filho
JS, Ashworth A and Turner NC: FGFR signaling promotes the growth of
triple-negative and basal-like breast cancer cell lines both in
vitro and in vivo. Clin Cancer Res. 17:5275–5286. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Spanheimer PM, Lorenzen AW, De Andrade JP,
Kulak MV, Carr JC, Woodfield GW, Sugg SL and Weigel RJ: Receptor
tyrosine kinase expression predicts response to sunitinib in breast
cancer. Ann Surg Oncol. 22:4287–4294. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yan S, Jiao X, Zou H and Li K: Prognostic
significance of c-Met in breast cancer: A meta-analysis of 6010
cases. Diagn Pathol. 10:622015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Burness ML, Grushko TA and Olopade OI:
Epidermal growth factor receptor in triple-negative and basal-like
breast cancer: Promising clinical target or only a marker? Cancer
J. 16:23–32. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Siziopikou KP, Ariga R, Proussaloglou KE,
Gattuso P and Cobleigh M: The challenging estrogen
receptor-negative/progesterone receptor-negative/HER-2-negative
patient: A promising candidate for epidermal growth factor
receptor-targeted therapy? Breast J. 12:360–362. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bayraktar S and Glück S: Molecularly
targeted therapies for metastatic triple-negative breast cancer.
Breast Cancer Res Treat. 138:21–35. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hsiao YC, Yeh MH, Chen YJ, Liu JF, Tang CH
and Huang WC: Lapatinib increases motility of triple-negative
breast cancer cells by decreasing miRNA-7 and inducing
Raf-1/MAPK-dependent interleukin-6. Oncotarget. 6:37965–37978.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Agazie YM and Hayman MJ: Molecular
mechanism for a role of SHP2 in epidermal growth factor receptor
signaling. Mol Cell Biol. 23:7875–7886. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Matalkah F, Martin E, Zhao H and Agazie
YM: SHP2 acts both upstream and downstream of multiple receptor
tyrosine kinases to promote basal-like and triple-negative breast
cancer. Breast Cancer Res. 18:22016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim HR, Jung KH, Im SA, Im YH, Kang SY,
Park KH, Lee S, Kim SB, Lee KH, Ahn JS, et al: Multicentre phase II
trial of bevacizumab combined with docetaxel-carboplatin for the
neoadjuvant treatment of triple-negative breast cancer (KCSG
BR-0905). Ann Oncol. 24:1485–1490. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gerber B, Loibl S, Eidtmann H, Rezai M,
Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C,
et al: Neoadjuvant bevacizumab and anthracycline-taxane-based
chemotherapy in 678 triple-negative primary breast cancers; results
from the geparquinto study (GBG 44). Ann Oncol. 24:2978–2984. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bartholomeusz C, Xie X, Pitner MK, Kondo
K, Dadbin A, Lee J, Saso H, Smith PD, Dalby KN and Ueno NT: MEK
inhibitor selumetinib (AZD6244; ARRY-142886) prevents lung
metastasis in a triple-negative breast cancer xenograft model. Mol
Cancer Ther. 14:2773–2781. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Giltnane JM and Balko JM: Rationale for
targeting the Ras/MAPK pathway in triple-negative breast cancer.
Discov Med. 17:275–283. 2014.PubMed/NCBI
|
|
27
|
Bartholomeusz C, Gonzalez-Angulo AM, Liu
P, Hayashi N, Lluch A, Ferrer-Lozano J and Hortobágyi GN: High ERK
protein expression levels correlate with shorter survival in
triple-negative breast cancer patients. Oncologist. 17:766–774.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Loi S, Dushyanthen S, Beavis PA, Salgado
R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV,
et al: RAS/MAPK activation is associated with reduced
tumor-infiltrating lymphocytes in triple-negative breast cancer:
Therapeutic cooperation between MEK and PD-1/PD-L1 immune
checkpoint inhibitors. Clin Cancer Res. 22:1499–1509. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rameh LE and Cantley LC: The role of
phosphoinositide 3-kinase lipid products in cell function. J Biol
Chem. 274:8347–8350. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Baselga J: Targeting the
phosphoinositide-3 (PI3) kinase pathway in breast cancer.
Oncologist. 16 Suppl 1:S12–S19. 2011. View Article : Google Scholar
|
|
31
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Salmena L, Carracedo A and Pandolfi PP:
Tenets of PTEN tumor suppression. Cell. 133:403–414. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Meric-Bernstam F and Gonzalez-Angulo AM:
Targeting the mTOR signaling network for cancer therapy. J Clin
Oncol. 27:2278–2287. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cossu-Rocca P, Orrù S, Muroni MR, Sanges
F, Sotgiu G, Ena S, Pira G, Murgia L, Manca A, Uras MG, et al:
Analysis of PIK3CA mutations and activation pathways in triple
negative breast cancer. PLoS One. 10:e01417632015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cancer Genome Atlas Network, .
Comprehensive molecular portraits of human breast tumours. Nature.
490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Korkaya H, Paulson A, Charafe-Jauffret E,
Ginestier C, Brown M, Dutcher J, Clouthier SG and Wicha MS:
Regulation of mammary stem/progenitor cells by
PTEN/Akt/beta-catenin signaling. PLoS Biol. 7:e10001212009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shrivastava S, Kulkarni P, Thummuri D,
Jeengar MK, Naidu VG, Alvala M, Redddy GB and Ramakrishna S:
Piperlongumine, an alkaloid causes inhibition of PI3K/Akt/mTOR
signaling axis to induce caspase-dependent apoptosis in human
triple-negative breast cancer cells. Apoptosis. 19:1148–1164. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chin YR, Yoshida T, Marusyk A, Beck AH,
Polyak K and Toker A: Targeting Akt3 signaling in triple-negative
breast cancer. Cancer Res. 74:964–973. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Montero JC, Esparis-Ogando A, Re-Louhau
MF, Seoane S, Abad M, Calero R, Ocaña A and Pandiella A: Active
kinase profiling, genetic and pharmacological data define mTOR as
an important common target in triple-negative breast cancer.
Oncogene. 33:148–156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Baselga J, Campone M, Piccart M, Burris HA
III, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun
F, et al: Everolimus in postmenopausal hormone-receptor-positive
advanced breast cancer. N Engl J Med. 366:520–529. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Beuvink I, Boulay A, Fumagalli S,
Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA and
Thomas G: The mTOR inhibitor RAD001 sensitizes tumor cells to
DNA-damaged induced apoptosis through inhibition of p21
translation. Cell. 120:747–759. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Singh J, Novik Y, Stein S, Volm M, Meyers
M, Smith J, Omene C, Speyer J, Schneider R, Jhaveri K, et al: Phase
2 trial of everolimus and carboplatin combination in patients with
triple negative metastatic breast cancer. Breast Cancer Res.
16:R322014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ganesan P, Moulder S, Lee JJ, Janku F,
Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, et al:
Triple-negative breast cancer patients treated at MD Anderson
Cancer Center in phase I trials: Improved outcomes with combination
chemotherapy and targeted agents. Mol Cancer Ther. 13:3175–3184.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ibrahim YH, Garcia-Garcia C, Serra V, He
L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J,
et al: PI3K inhibition impairs BRCA1/2 expression and sensitizes
BRCA-proficient triple-negative breast cancer to PARP inhibition.
Cancer Discov. 2:1036–1047. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Schuler M, Awada A, Harter P, Canon JL,
Possinger K, Schmidt M, De Grève J, Neven P, Dirix L, Jonat W, et
al: A phase II trial to assess efficacy and safety of afatinib in
extensively pretreated patients with HER2-negative metastatic
breast cancer. Breast Cancer Res Treat. 134:1149–1159. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bernsdorf M, Ingvar C, Jörgensen L, Tuxen
MK, Jakobsen EH, Saetersdal A, Kimper-Karl ML, Kroman N, Balslev E
and Ejlertsen B: Effect of adding gefitinib to neoadjuvant
chemotherapy in estrogen receptor negative early breast cancer in a
randomized phase II trial. Breast Cancer Res Treat. 126:463–470.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mailliez A, Baldini C, Van JT, Servent V,
Mallet Y and Bonneterre J: Nasal septum perforation: A side effect
of bevacizumab chemotherapy in breast cancer patients. Br J Cancer.
103:772–775. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Scott AJ, Messersmith WA and Jimeno A:
Apatinib: A promising oral antiangiogenic agent in the treatment of
multiple solid tumors. Drugs Today (Barc). 51:223–229. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hong DS, Garrido-Laguna I, Ekmekcioglu S,
Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S,
Tsimberidou AM, et al: Dual inhibition of the vascular endothelial
growth factor pathway: A phase 1 trial evaluating bevacizumab and
AZD2171 (cediranib) in patients with advanced solid tumors. Cancer.
120:2164–2173. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Tolaney SM, Tan S, Guo H, Barry W, Van
Allen E, Wagle N, Brock J, Larrabee K, Paweletz C, Ivanova E, et
al: Phase II study of tivantinib (ARQ 197) in patients with
metastatic triple-negative breast cancer. Invest New Drugs.
33:1108–1114. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tolaney SM, Ziehr DR, Guo H, Ng MR, Barry
WT, Higgins MJ, Isakoff SJ, Brock JE, Ivanova EV, Paweletz CP, et
al: Phase II and biomarker study of cabozantinib in metastatic
triple-negative breast cancer patients. Oncologist. 22:25–32. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Soria JC, DeBraud F, Bahleda R, Adamo B,
Andre F, Dienstmann R, Delmonte A, Cereda R, Isaacson J, Litten J,
et al: Phase I/IIa study evaluating the safety, efficacy,
pharmacokinetics, and pharmacodynamics of lucitanib in advanced
solid tumors. Ann Oncol. 25:2244–2251. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wu YL, Zhang LI, Trandafir L, Dong T,
Duval V, Hazell K and Xu B: Phase I study of the Pan-PI3K inhibitor
buparlisib in adult chinese patients with advanced solid tumors.
Anticancer Res. 36:6185–6194. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Juric D, Krop I, Ramanathan RK, Wilson TR,
Ware JA, Sanabria Bohorquez SM, Savage HM, Sampath D, Salphati L,
Lin RS, et al: Phase I dose-escalation study of taselisib, an oral
PI3K inhibitor, in patients with advanced solid tumors. Cancer
Discov. 7:704–715. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Tamura K, Hashimoto J, Tanabe Y, Kodaira
M, Yonemori K, Seto T, Hirai F, Arita S, Toyokawa G, Chen L, et al:
Safety and tolerability of AZD5363 in Japanese patients with
advanced solid tumors. Cancer Chemother Pharmacol. 77:787–795.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Doi T, Tamura K, Tanabe Y, Yonemori K,
Yoshino T, Fuse N, Kodaira M, Bando H, Noguchi K, Shimamoto T and
Ohtsu A: Phase 1 pharmacokinetic study of the oral pan-AKT
inhibitor MK-2206 in Japanese patients with advanced solid tumors.
Cancer Chemother Pharmacol. 76:409–416. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Saura C, Roda D, Roselló S, Oliveira M,
Macarulla T, Pérez-Fidalgo JA, Morales-Barrera R, Sanchis-García
JM, Musib L, Budha N, et al: A first-in-human phase I study of the
ATP-competitive AKT inhibitor ipatasertib demonstrates robust and
safe targeting of AKT in patients with solid tumors. Cancer Discov.
7:102–113. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Pascual T, Apellániz-Ruiz M, Pernaut C,
Cueto-Felgueroso C, Villalba P, Álvarez C, Manso L, Inglada-Pérez
L, Robledo M, Rodríguez-Antona C and Ciruelos E: Polymorphisms
associated with everolimus pharmacokinetics, toxicity and survival
in metastatic breast cancer. PLoS One. 12:e01801922017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Chiu JW, Hotte SJ, Kollmannsberger CK,
Renouf DJ, Cescon DW, Hedley D, Chow S, Moscow J, Chen Z, Perry M,
et al: A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386)
and temsirolimus in advanced solid tumors (PJC008/NCI 9041). Invest
New Drugs. 34:104–111. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Schwartzberg LS, Yardley DA, Elias AD,
Patel M, LoRusso P, Burris HA, Gucalp A, Peterson AC, Blaney ME,
Steinberg JL, et al: A Phase I/Ib study of enzalutamide alone and
in combination with endocrine therapies in women with advanced
breast cancer. Clin Cancer Res. 23:4046–4054. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Drew Y, Ledermann J, Hall G, Rea D,
Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D,
et al: Phase 2 multicentre trial investigating intermittent and
continuous dosing schedules of the poly(ADP-ribose) polymerase
inhibitor rucaparib in germline BRCA mutation carriers with
advanced ovarian and breast cancer. Br J Cancer. 114:e212016.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
O'Shaughnessy J, Schwartzberg L, Danso MA,
Miller KD, Rugo HS, Neubauer M, Robert N, Hellerstedt B, Saleh M,
Richards P, et al: Phase III study of iniparib plus gemcitabine and
carboplatin versus gemcitabine and carboplatin in patients with
metastatic triple-negative breast cancer. J Clin Oncol.
32:3840–3847. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Nishikawa T, Matsumoto K, Tamura K,
Yoshida H, Imai Y, Miyasaka A, Onoe T, Yamaguchi S, Shimizu C,
Yonemori K, et al: Phase 1 dose-escalation study of single-agent
veliparib in Japanese patients with advanced solid tumors. Cancer
Sci. 108:1834–1842. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
de Bono J, Ramanathan RK, Mina L, Chugh R,
Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, et al:
Phase I, dose-escalation, two-part trial of the PARP inhibitor
talazoparib in patients with advanced germline BRCA1/2 mutations
and selected sporadic cancers. Cancer Discov. 7:620–629. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Robson M, Im SA, Senkus E, Xu B, Domchek
SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, et al:
Olaparib for metastatic breast cancer in patients with a germline
BRCA mutation. N Engl J Med. 377:523–533. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Nanda R, Chow LQ, Dees EC, Berger R, Gupta
S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, et al:
Pembrolizumab in patients with advanced triple-negative breast
cancer: Phase Ib KEYNOTE-012 study. J Clin Oncol. 34:2460–2467.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Lee JM, Cimino-Mathews A, Peer CJ, Zimmer
A, Lipkowitz S, Annunziata CM, Cao L, Harrell MI, Swisher EM,
Houston N, et al: Safety and clinical activity of the programmed
death-ligand 1 inhibitor durvalumab in combination with poly
(ADP-Ribose) polymerase inhibitor olaparib or vascular endothelial
growth factor receptor 1–3 inhibitor cediranib in women's cancers:
A dose-escalation, phase I study. J Clin Oncol. 35:2193–2202. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Hoeflich KP, O'Brien C, Boyd Z, Cavet G,
Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, et
al: In vivo antitumor activity of MEK and phosphatidylinositol
3-kinase inhibitors in basal-like breast cancer models. Clin Cancer
Res. 15:4649–4664. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Britten CD: PI3K and MEK inhibitor
combinations: Examining the evidence in selected tumor types.
Cancer Chemother Pharmacol. 71:1395–1409. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Nieto MA: Epithelial plasticity: A common
theme in embryonic and cancer cells. Science. 342:12348502013.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Al Moustafa AE, Achkhar A and Yasmeen A:
EGF-receptor signaling and epithelial-mesenchymal transition in
human carcinomas. Front Biosci (Schol Ed). 4:671–684. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Gonzalez DM and Medici D: Signaling
mechanisms of the epithelial-mesenchymal transition. Sci Signal.
7:re82014. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Guarino M: Src signaling in cancer
invasion. J Cell Physiol. 223:14–26. 2010.PubMed/NCBI
|
|
74
|
Hung CM, Kuo DH, Chou CH, Su YC, Ho CT and
Way TD: Osthole suppresses hepatocyte growth factor (HGF)-induced
epithelial-mesenchymal transition via repression of the
c-Met/Akt/mTOR pathway in human breast cancer cells. J Agric Food
Chem. 59:9683–9690. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Kang Y and Massagué J:
Epithelial-mesenchymal transitions: Twist in development and
metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Sivakumar R, Koga H, Selvendiran K,
Maeyama M, Ueno T and Sata M: Autocrine loop for IGF-I receptor
signaling in SLUG-mediated epithelial-mesenchymal transition. Int J
Oncol. 34:329–338. 2009.PubMed/NCBI
|
|
77
|
Vincent-Salomon A and Thiery JP: Host
microenvironment in breast cancer development:
Epithelial-mesenchymal transition in breast cancer development.
Breast Cancer Res. 5:101–106. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
78
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Foroni C, Broggini M, Generali D and Damia
G: Epithelial-mesenchymal transition and breast cancer: Role,
molecular mechanisms and clinical impact. Cancer Treat Rev.
38:689–697. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Prat A, Parker JS, Karginova O, Fan C,
Livasy C, Herschkowitz JI, He X and Perou CM: Phenotypic and
molecular characterization of the claudin-low intrinsic subtype of
breast cancer. Breast Cancer Res. 12:R682010. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Singh R and Mo YY: Role of microRNAs in
breast cancer. Cancer Biol Ther. 14:201–212. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Rhodes LV, Martin EC, Segar HC, Miller DF,
Buechlein A, Rusch DB, Nephew KP, Burow ME and Collins-Burow BM:
Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the
inhibition of epithelial-to-mesenchymal transition in
triple-negative breast cancer. Oncotarget. 6:16638–16652. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Ito K, Park SH, Nayak A, Byerly JH and
Irie HY: PTK6 inhibition suppresses metastases of triple-negative
breast cancer via SNAIL-Dependent E-cadherin regulation. Cancer
Res. 76:4406–4417. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Ginestier C, Hur MH, Charafe-Jauffret E,
Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG,
Liu S, et al: ALDH1 is a marker of normal and malignant human
mammary stem cells and a predictor of poor clinical outcome. Cell
Stem Cell. 1:555–567. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Rhodes LV, Tate CR, Segar HC, Burks HE,
Phamduy TB, Hoang V, Elliott S, Gilliam D, Pounder FN, Anbalagan M,
et al: Suppression of triple-negative breast cancer metastasis by
pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT
master regulators. Breast Cancer Res Treat. 145:593–604. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Kahn M: Can we safely target the WNT
pathway? Nat Rev Drug Discov. 13:513–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Conacci-Sorrell M, Simcha I, Ben-Yedidia
T, Blechman J, Savagner P and Ben-Ze'ev A: Autoregulation of
E-cadherin expression by cadherin-cadherin interactions: The roles
of beta-catenin signaling, Slug, and MAPK. J Cell Biol.
163:847–857. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Howe LR, Watanabe O, Leonard J and Brown
AM: Twist is up-regulated in response to Wnt1 and inhibits mouse
mammary cell differentiation. Cancer Res. 63:1906–1913.
2003.PubMed/NCBI
|
|
92
|
MacDonald BT, Tamai K and He X:
Wnt/beta-catenin signaling: Components, mechanisms, and diseases.
Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Dey N, Barwick BG, Moreno CS,
Ordanic-Kodani M, Chen Z, Oprea-Ilies G, Tang W, Catzavelos C,
Kerstann KF, Sledge GW Jr, et al: Wnt signaling in triple negative
breast cancer is associated with metastasis. BMC Cancer.
13:5372013. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Li Y, Li PK, Roberts MJ, Arend RC, Samant
RS and Buchsbaum DJ: Multi-targeted therapy of cancer by
niclosamide: A new application for an old drug. Cancer Lett.
349:8–14. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Londoño-Joshi AI, Arend RC, Aristizabal L,
Lu W, Samant RS, Metge BJ, Hidalgo B, Grizzle WE, Conner M,
Forero-Torres A, et al: Effect of niclosamide on basal-like breast
cancers. Mol Cancer Ther. 13:800–811. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Koval A, Ahmed K and Katanaev VL:
Inhibition of Wnt signalling and breast tumour growth by the
multi-purpose drug suramin through suppression of heterotrimeric G
proteins and Wnt endocytosis. Biochem J. 473:371–381. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Nam JS, Suchar AM, Kang MJ, Stuelten CH,
Tang B, Michalowska AM, Fisher LW, Fedarko NS, Jain A, Pinkas J, et
al: Bone sialoprotein mediates the tumor cell-targeted
prometastatic activity of transforming growth factor beta in a
mouse model of breast cancer. Cancer Res. 66:6327–6335. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Zu X, Zhang Q, Cao R, Liu J, Zhong J, Wen
G and Cao D: Transforming growth factor-β signaling in tumor
initiation, progression and therapy in breast cancer: An update.
Cell Tissue Res. 347:73–84. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Shi Y and Massagué J: Mechanisms of
TGF-beta signaling from cell membrane to the nucleus. Cell.
113:685–700. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Katz LH, Li Y, Chen JS, Muñoz NM, Majumdar
A, Chen J and Mishra L: Targeting TGF-β signaling in cancer. Expert
Opin Ther Targets. 17:743–760. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Valcourt U, Kowanetz M, Niimi H, Heldin CH
and Moustakas A: TGF-beta and the Smad signaling pathway support
transcriptomic reprogramming during epithelial-mesenchymal cell
transition. Mol Biol Cell. 16:1987–2002. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Massagué J: TGFbeta in cancer. Cell.
134:215–230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Kim S, Lee J, Jeon M, Lee JE and Nam SJ:
Zerumbone suppresses the motility and tumorigenecity of triple
negative breast cancer cells via the inhibition of TGF-β1 signaling
pathway. Oncotarget. 7:1544–1558. 2016.PubMed/NCBI
|
|
104
|
Wahdan-Alaswad R, Harrell JC, Fan Z,
Edgerton SM, Liu B and Thor AD: Metformin attenuates transforming
growth factor beta (TGF-β) mediated oncogenesis in mesenchymal
stem-like/claudin-low triple negative breast cancer. Cell Cycle.
15:1046–1059. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Bhola NE, Balko JM, Dugger TC, Kuba MG,
Sánchez V, Sanders M, Stanford J, Cook RS and Arteaga CL: TGF-β
inhibition enhances chemotherapy action against triple-negative
breast cancer. J Clin Invest. 123:1348–1358. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Purrington KS, Visscher DW, Wang C,
Yannoukakos D, Hamann U, Nevanlinna H, Cox A, Giles GG,
Eckel-Passow JE, Lakis S, et al: Genes associated with
histopathologic features of triple negative breast tumors predict
molecular subtypes. Breast Cancer Res Treat. 157:117–131. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Collins LC, Cole KS, Marotti JD, Hu R,
Schnitt SJ and Tamimi RM: Androgen receptor expression in breast
cancer in relation to molecular phenotype: Results from the nurses'
health study. Mod Pathol. 24:924–931. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Liao DJ and Dickson RB: Roles of androgens
in the development, growth, and carcinogenesis of the mammary
gland. J Steroid Biochem Mol Biol. 80:175–189. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Hickey TE, Robinson JL, Carroll JS and
Tilley WD: Minireview: the androgen receptor in breast tissues:
Growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol.
26:1252–1267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Gucalp A and Traina TA: Triple-negative
breast cancer: Role of the androgen receptor. Cancer J. 16:62–65.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Gucalp A, Tolaney S, Isakoff SJ, Ingle JN,
Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, et al:
Phase II trial of bicalutamide in patients with androgen
receptor-positive, estrogen receptor-negative metastatic breast
cancer. Clin Cancer Res. 19:5505–5512. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Lehmann BD, Bauer JA, Schafer JM,
Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H,
Arteaga CL, et al: PIK3CA mutations in androgen receptor-positive
triple negative breast cancer confer sensitivity to the combination
of PI3K and androgen receptor inhibitors. Breast Cancer Res.
16:4062014. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Cuenca-López Md, Montero JC, Morales JC,
Prat A, Pandiella A and Ocana A: Phospho-kinase profile of triple
negative breast cancer and androgen receptor signaling. BMC Cancer.
14:3022014. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Maugeri-Saccà M, Bartucci M and De Maria
R: DNA damage repair pathways in cancer stem cells. Mol Cancer
Ther. 11:1627–1636. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Pierce AJ, Stark JM, Araujo FD, Moynahan
ME, Berwick M and Jasin M: Double-strand breaks and tumorigenesis.
Trends Cell Biol. 11:S52–S59. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Powell SN and Kachnic LA: Roles of BRCA1
and BRCA2 in homologous recombination, DNA replication fidelity and
the cellular response to ionizing radiation. Oncogene.
22:5784–5791. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Bouwman P and Jonkers J: The effects of
deregulated DNA damage signalling on cancer chemotherapy response
and resistance. Nat Rev Cancer. 12:587–598. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Stevens KN, Vachon CM and Couch FJ:
Genetic susceptibility to triple-negative breast cancer. Cancer
Res. 73:2025–2030. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Atchley DP, Albarracin CT, Lopez A, Valero
V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN and Arun BK: Clinical
and pathologic characteristics of patients with BRCA-positive and
BRCA-negative breast cance. J Clin Oncol. 26:4282–4288. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Goodwin PJ, Phillips KA, West DW, Ennis M,
Hopper JL, John EM, O'Malley FP, Milne RL, Andrulis IL, Friedlander
ML, et al: Breast cancer prognosis in BRCA1 and BRCA2 mutation
carriers: An international prospective breast cancer family
registry population-based cohort study. J Clin Oncol. 30:19–26.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Stoppa-Lyonnet D, Ansquer Y, Dreyfus H,
Gautier C, Gauthier-Villars M, Bourstyn E, Clough KB, Magdelénat H,
Pouillart P, Vincent-Salomon A, et al: Familial invasive breast
cancers: Worse outcome related to BRCA1 mutations. J Clin Oncol.
18:4053–4059. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Rummel S, Varner E, Shriver CD and
Ellsworth RE: Evaluation of BRCA1 mutations in an unselected
patient population with triple-negative breast cancer. Breast
Cancer Res Treat. 137:119–125. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Hoeijmakers JH: Genome maintenance
mechanisms for preventing cancer. Nature. 411:366–374. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
O'Shaughnessy J, Osborne C, Pippen JE,
Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM and Bradley C:
Iniparib plus chemotherapy in metastatic triple-negative breast
cancer. N Engl J Med. 364:205–214. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Dent RA, Lindeman GJ, Clemons M, Wildiers
H, Chan A, McCarthy NJ, Singer CF, Lowe ES, Watkins CL and
Carmichael J: Phase I trial of the oral PARP inhibitor olaparib in
combination with paclitaxel for first- or second-line treatment of
patients with metastatic triple-negative breast cancer. Breast
Cancer Res. 15:R882013. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Ollier M, Radosevic-Robin N, Kwiatkowski
F, Ponelle F, Viala S, Privat M, Uhrhammer N, Bernard-Gallon D,
Penault-Llorca F, Bignon YJ and Bidet Y: DNA repair genes
implicated in triple negative familial non-BRCA1/2 breast cancer
predisposition. Am J Cancer Res. 5:2113–2126. 2015.PubMed/NCBI
|
|
127
|
Alshareeda AT, Negm OH, Aleskandarany MA,
Green AR, Nolan C, TigHhe PJ, Madhusudan S, Ellis IO and Rakha EA:
Clinical and biological significance of RAD51 expression in breast
cancer: A key DNA damage response protein. Breast Cancer Res Treat.
159:41–53. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Loi S, Michiels S, Salgado R, Sirtaine N,
Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V,
Desmedt C, et al: Tumor infiltrating lymphocytes are prognostic in
triple negative breast cancer and predictive for trastuzumab
benefit in early breast cancer: Results from the FinHER trial. Ann
Oncol. 25:1544–1550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Adams S, Gray RJ, Demaria S, Goldstein L,
Perez EA, Shulman LN, Martino S, Wang M, Jones VE and Saphner TJ:
Prognostic value of tumor-infiltrating lymphocytes in
triple-negative breast cancers from two phase III randomized
adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin
Oncol. 32:2959–2966. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Loi S, Sirtaine N, Piette F, Salgado R,
Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, et al:
Prognostic and predictive value of tumor-infiltrating lymphocytes
in a phase III randomized adjuvant breast cancer trial in
node-positive breast cancer comparing the addition of docetaxel to
doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin
Oncol. 31:860–867. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Adams S, Goldstein LJ, Sparano JA, Demaria
S and Badve SS: Tumor infiltrating lymphocytes (TILs) improve
prognosis in patients with triple negative breast cancer (TNBC).
Oncoimmunology. 4:e9859302015. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Criscitiello C and Curigliano G:
Immunotherapy of breast cancer. Prog Tumor Res. 42:30–43. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Mittendorf EA, Philips AV, Meric-Bernstam
F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM,
Akcakanat A, et al: PD-L1 expression in triple-negative breast
cancer. Cancer Immunol Res. 2:361–370. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Immunotherapy slows TNBC progression.
Cancer Discov. 5:5702015. View Article : Google Scholar
|
|
137
|
Gholami S, Chen CH, Gao S, Lou E, Fujisawa
S, Carson J, Nnoli JE, Chou TC, Bromberg J and Fong Y: Role of MAPK
in oncolytic herpes viral therapy in triple-negative breast cancer.
Cancer Gene Ther. 21:283–289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Bramati A, Girelli S, Torri V, Farina G,
Galfrascoli E, Piva S, Moretti A, Dazzani MC, Sburlati P and La
Verde NM: Efficacy of biological agents in metastatic
triple-negative breast cancer. Cancer Treat Rev. 40:605–613. 2014.
View Article : Google Scholar : PubMed/NCBI
|
